Background: Some studies have shown that pre-transplant cytomegalovirus (CMV)
| INTRODUC TI ON
Diagnostic methods and strategies for CMV prevention and treatment have improved significantly over the past 20 years, significantly reducing direct morbidity and mortality associated with CMV disease after solid organ transplantation.
1 CMV infection in the transplant setting is associated with indirect effects, encompassing both significant immunomodulation and inflammation which may induce allogeneic immune responses to the heart allograft. 2, 3 These indirect effects have been hypothesized to impact both heart graft and patient survival especially cardiac allograft vasculopathy (CAV) in early studies. However, this association has become more uncertain in the most recent era of antiviral prophylaxis. 3, 4 Risk stratification of heart transplant recipients based on pretransplant donor/recipient CMV serostatus is a key element of preventing post-transplant CMV infection and disease.
1 An analysis of registry data has shown an association between donor and recipient CMV serostatus and mortality in heart transplant recipients. 5 Since pre-transplant CMV donor (D)/recipient (R) serology determines the relative risk of CMV infection and disease, it has been hypothesized that it may also influence mortality.
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The objective of this study was to investigate the relationship between pre-transplant CMV donor and recipient serostatus and long-term mortality in a retrospective cohort of heart transplant recipients transplanted at our center over a 30 year period.
| PATIENTS AND ME THODS

| Study population
We analyzed all adult heart transplants performed at the University of Alberta Hospital between July 1985 and December 2015. 
| Donor-recipient CMV risk category
| Transplant era
Throughout the entire study period, D−/R− recipients did not receive CMV antiviral prophylaxis or routine CMV surveillance.
Three eras of CMV prevention strategies that were applied to D+/R− and R+ recipients were defined: Era 1 (July 1985 to April 1998) was pre-ganciclovir. In Era 1, only D+/R− patients received targeted 3 months of universal prophylaxis which included CMV hyperimmune globulin alone before June 1990, high-dose oral acyclovir between June 1990-August 1996, and preemptive intravenous ganciclovir triggered by 3 months of antigenemia monitoring from September 1996-April 1998. R+ recipients had laboratory monitoring performed for evidence of infection over the first year, but were only treated if symptomatic. Era 2 began in May 1998 and lasted until December 2004, and recipients received oral ganciclovir (1000 mg tid) for prophylaxis. D+/R− heart transplants received 3 months of universal prophylaxis; a preemptive strategy was used in R+ heart transplant recipients who were monitored for 3 months using antigenemia/CMV DNAemia surveillance and treated at trigger levels with intravenous ganciclovir. Era 3 is the current era (January 2005-December 2015) of oral valganciclovir prophylaxis (900 mg daily). During this era, all D+/R− hearts and R+ heart transplant recipients receiving anti-thymocyte induction therapy received 3 months of universal valganciclovir prophylaxis. Other R+ heart recipients were managed using a preemptive strategy with 3 months of routine surveillance for CMV DNAemia and treatment with intravenous ganciclovir or valganciclovir when required. CMV prevention strategies used in each era are summarized in Table S1 .
| CMV infection
The definition of CMV infection was based on recently published guidelines for use in clinical trials. 10 CMV infection data was collected using the date of first positive CMV detection within 2 years of transplant. Testing results were retrieved from virology laboratory paper (pre-1992) and laboratory information system records.
Methods used to detect CMV varied over time. Prior to August 1996, rapid shell vial tissue culture assays were used to detect infectious CMV in serially tested urine and throat swab samples.
Additional samples such as buffy coat, bronchoalveolar lavage and biopsy samples were tested when patients were symptomatic. A pp65 antigenemia assay was introduced in August 1996 followed by plasma testing for CMV DNA using a laboratory-developed quanti- 
| Follow-up data
Data on each patient were collected from time of first transplant until 31 December 2016. For patients not followed in Alberta the date the patient was transferred out was considered the last date of follow-up.
When this was not available the last date of CMV testing was used as the last follow-up date. Patients who underwent re-transplantation were censored at time of re-transplant and the subsequent event was followed until the date of last follow-up while accounting for updated D/R CMV serostatus and infection post transplant.
| Primary outcome variable
The primary outcome for this study was all-cause mortality at 10 years.
Mortality data were collected prospectively and extracted from the heart program database.
| Statistical analysis
Survival analysis at 10 years post transplant was performed using the Kaplan-Meier method, and curves were compared using logrank test. Pairwise comparisons were adjusted using the BenjaminiHochberg procedure. To identify risk factors associated with 10 year mortality, a Cox regression multivariate model was generated, treating CMV infection as a time-dependent variable. Hazard ratios were calculated for each variable, representing the ratio of risk of death at 10 years, or the probability of surviving at any given time, provided that death has not yet occurred. Survival analysis was performed using R 3.5.1 and Cox regression was performed using IBM SPSS 24.
| RE SULTS
| Study population
We analyzed a total of 620 heart transplants in 603 patients (17 retransplantations) occurring within the study period as described in Table 1 F I G U R E 1 Survival of heart transplant recipients according to D/R CMV serostatus. Kaplan-Meier estimates of survival at 10 y were generated for D/R CMV group over the entire study period. The risk table indicates the number of patients still at risk of death at each year post transplant. At 10 y, the estimated survival was 62.9% for D−/R−, 58.3% for D−/R+, 54.8% for D+/R+, and 68.8% for D+/R− patients. Differences in survival were not statistically significant when compared using log-rank test (P = 0.11). CMV, cytomegalovirus and no change (n = 5). Twenty percent of heart recipients were CMV mismatched at transplantation with nearly a third of heart transplants occurring in each era. Thirty-eight percent of heart recipients had incident CMV infection within 2 years post transplant. Patient characteristics within each CMV serostatus group and transplant era are included in Tables S2 and S3 , respectively. The proportion of mismatched patients did not differ across eras among heart recipients (chi-square test, P = 0.56).
| Impact of D/R CMV serostatus on survival in heart transplant recipients
Overall mortality in our cohort of heart transplant recipients at 10 years was 35.2%. The Kaplan-Meier survival estimates according to D/R CMV serostatus are shown in Figure 1 . Overall, there was no significant difference in estimated survival between groups (log-rank test, P = 0.11).
Era effects for D−/R− recipients were explored in Figure 2 . The survival of D−/R− recipients was not significantly different across eras (log-rank test, P = 0.8). In Figure 3 , we explored the era effect on patients at risk of CMV infection (D−/R+, D+/R+, and D+/R−) and found that survival was significantly different (log-rank test, P = 0.043) among eras, although pairwise comparisons were not significant after BH-adjustment (pre-ganciclovir era vs oral ganciclovir era BH-adjusted P = 0.2, pre-ganciclovir era vs oral valganciclovir era BH-adjusted P = 0.08).
A Cox proportional-hazards model was fit to the data, and the univariate and multivariate analysis of predictive variables are reported for heart recipients in Table 2 . Age at transplant and recipient sex were not significantly associated with 10 year mortality (P = 0.13 and 0.87 respectively). Patients considered "at risk for CMV infection"
were not found to have significantly greater mortality at 10 years compared to patients considered having "no risk for CMV infection" (D−/R+ P=0.42, D+/R+ P=0.11, D+/R− P = 0.49). As well, time-dependent CMV infection was not found to be significantly associated with mortality at 10 years (P = 0.18). An era effect was observed in a univariate analysis as recipients transplanted in the valganciclovir era were found to have an estimated 29.4% (95% CI: 1.1%-49.7%) reduced risk of death at 10 years compared to recipients transplanted in the pre-ganciclovir era (P = 0.043), and this result was also observed in the final risk-adjusted multivariate model, where transplantation in the valganciclovir era was a significant predictor of survival with an estimated reduced risk of death at 10 years of 29.3% (95% CI:
0.04%-49.9%, P = 0.047) after controlling for age at transplant, D/R CMV serology and CMV infection.
| D ISCUSS I ON
In our study of heart transplant recipients followed from the beginning of our transplantation program, donor/recipient CMV F I G U R E 2 Survival of D−/R− heart transplant recipients according to transplant era. Kaplan-Meier estimates of survival at 10 y were generated for D/R CMV group over the entire study period. The risk table indicates the number of patients still at risk of death at each year post transplant. The estimated survival at 10 y of D−/R− patients was 62.5% for those transplanted in Era 1, 67% for Era 2% and 60.8% for Era 3. Differences in survival were not statistically significant when compared using log-rank test (P = 0.8). CMV, cytomegalovirus serostatus was not found to be an independent predictor of 10 year survival. Transplant era alone was found to be associated with survival of heart transplant recipients.
Registry data have previously been used to analyze the impact
of CMV on long-term mortality but only one study included heart transplants. 5 In there is increasing interest on the indirect effects of CMV infection related to longer term graft function. CMV infection has been linked to CAV in hearts 1,3,13 and is viewed as a major limiting factor in long-term survival and is a frequent cause or comorbidity associated with death. 12, [14] [15] [16] [17] In our study we did not directly evaluate whether the development of indirect effects in the form of allograft dysfunction were related to CMV. In addition, heart transplant patients are also at risk of general indirect effects of CMV infection such as bacterial and fungal infection, acute rejection and increased risk of post-transplant lymphoproliferative disorder which might impact mortality.
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In our study, we selected transplant eras based on the emergence of newer CMV antiviral therapies and found that neither CMV serostatus nor evidence of CMV infection impacted survival in heart transplant recipients. Surgical techniques, immunosuppression regimens, and strategies for the prevention and management of other infections have improved over time, and these non-CMV effects may be reducing mortality in the most recent valganciclovir era. However, we observed no difference in survival among eras in the D−/R− patients, and furthermore, we saw a reduction in mortality effect seen in the most recent era for our cohort compared to D−/R− patients, suggesting that the improved management of CMV in patients at risk may play a major role explaining the era effect.
A limitation of our study is that we did not quantitate CMV infection in the form of quantitative CMV DNAemia, CMV syndrome or F I G U R E 3 Survival of heart transplant recipients at risk for CMV infection according to transplant era. Kaplan-Meier estimates of survival at 10 y were generated for D/R CMV group over the entire study period. The risk table indicates the number of patients still at risk of death at each year post transplant. The estimated survival at 10 y of patients at risk of CMV infection was 52.4% for those transplanted in Era 1, 60.2% for Era 2% and 71.6% for Era 3. Differences in survival were statistically significant when compared using log-rank test (P = 0.043). CMV, cytomegalovirus disease. Others have suggested that CMV disease is associated with and increased risk of mortality in heart transplantation. 9 Although valganciclovir has not been shown to be superior to oral ganciclovir for CMV disease prevention, its significantly higher bioavailability and reduced pill burden make it the drug of choice . [18] [19] [20] It is possible that quantitative improvements in CMV prevention and management in the valganciclovir era may be contributing to the era effects on mortality we observed. However, our data suggest that although further improvements in our CMV management may improve posttransplant morbidity in heart recipients, further improvement on mortality may not be significant as the impact of CMV even in the current valganciclovir era on long-term mortality is minimal.
Our historical retrospective study has some inherent ad- events, all of which may have impacted survival were not available for analysis in our study. In addition, the duration of follow-up of patients transplanted in the recent years is shorter and there is some underrepresentation of patients receiving valganciclovir.
In conclusion, in our study, D/R CMV serostatus was not an independent predictor of long-term mortality in heart transplant recipients. Further studies analyzing larger recent cohorts of patients are warranted to validate our findings.
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